CTSD Gene - Cathepsin D

📖 Wiki Page

gene2704 wordssynced 2026-04-02

CTSD — Cathepsin D

...

CTSD — Cathepsin D

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">CTSD Gene - Cathepsin D</th>
</tr>
<tr>
<td class="label">Brain Region</td>
<td>CTSD Expression</td>
</tr>
<tr>
<td class="label">Substantia nigra pars compacta</td>
<td>Highest</td>
</tr>
<tr>
<td class="label">Hippocampus CA1</td>
<td>High</td>
</tr>
<tr>
<td class="label">Frontal cortex layer 5</td>
<td>Moderate-High</td>
</tr>
<tr>
<td class="label">CerebellarPurkinje cells</td>
<td>High</td>
</tr>
<tr>
<td class="label">Dorsal motor nucleus</td>
<td>High</td>
</tr>
<tr>
<td class="label">Locus coeruleus</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Spinal cord motor neurons</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>CTSD</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Cathepsin D</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>11p15.5</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>1509</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000160336</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P07339</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>116840</td>
</tr>
<tr>
<td class="label">Gene Type</td>
<td>Protein coding</td>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>Cathepsin D</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>52 kDa (prepro), 31 kDa (mature)</td>
</tr>
<tr>
<td class="label">Amino Acids</td>
<td>412 amino acids</td>
</tr>
<tr>
<td class="label">Subcellular Localization</td>
<td>Lysosome</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>Aspartyl protease (peptidase A1)</td>
</tr>
<tr>
<td class="label">Disease Stage</td>
<td>CTSD Activity</td>
</tr>
<tr>
<td class="label">Preclinical</td>
<td>Normal</td>
</tr>
<tr>
<td class="label">MCI</td>
<td>↑ 1.5x</td>
</tr>
<tr>
<td class="label">Mild AD</td>
<td>↑ 2-3x</td>
</tr>
<tr>
<td class="label">Moderate AD</td>
<td>Variable</td>
</tr>
<tr>
<td class="label">Severe AD</td>
<td>↓ in some regions</td>
</tr>
<tr>
<td class="label">AD Brain Region</td>
<td>Cathepsin D Activity</td>
</tr>
<tr>
<td class="label">Hippocampus</td>
<td>↑ 2-3x</td>
</tr>
<tr>
<td class="label">Frontal cortex</td>
<td>↑ 1.5x</td>
</tr>
<tr>
<td class="label">Cerebellum</td>
<td>Normal</td>
</tr>
<tr>
<td class="label">Entorhinal cortex</td>
<td>↑↑↑</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Pepstatin A analogs</td>
<td>Inhibits amyloidogenic cleavage</td>
</tr>
<tr>
<td class="label">Autophagy enhancers</td>
<td>mTOR inhibition (rapamycin)</td>
</tr>
<tr>
<td class="label">TFEB agonists</td>
<td>Increases lysosomal biogenesis</td>
</tr>
<tr>
<td class="label">Gene therapy AAV-CTSD</td>
<td>Supplementation</td>
</tr>
<tr>
<td class="label">Variant</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">c.631G>A (p.D211N)</td>
<td>Missense</td>
</tr>
<tr>
<td class="label">c.662T>C (p.L221P)</td>
<td>Missense</td>
</tr>
<tr>
<td class="label">c.1A>G (p.M1?)</td>
<td>Initiation</td>
</tr>
<tr>
<td class="label">c.270-1G>A</td>
<td>Splicing</td>
</tr>
<tr>
<td class="label">Protein</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">BACE1</td>
<td>Sequential cleavage of APP</td>
</tr>
<tr>
<td class="label">Presenilin</td>
<td>Gamma-secretase complex</td>
</tr>
<tr>
<td class="label">ATG5-7</td>
<td>Autophagosome formation</td>
</tr>
<tr>
<td class="label">LAMP2</td>
<td>Lysosomal membrane</td>
</tr>
<tr>
<td class="label">GBA</td>
<td>Lysosomal enzyme</td>
</tr>
<tr>
<td class="label">TFEB</td>
<td>Transcriptional regulation</td>
</tr>
<tr>
<td class="label">Element</td>
<td>Position</td>
</tr>
<tr>
<td class="label">TATA box</td>
<td>-25</td>
</tr>
<tr>
<td class="label">Inr</td>
<td>+1</td>
</tr>
<tr>
<td class="label">TFEB site</td>
<td>-200 to -180</td>
</tr>
<tr>
<td class="label">NFE2L2 ARE</td>
<td>-350 to -330</td>
</tr>
<tr>
<td class="label">NF-κB site</td>
<td>-500 to -480</td>
</tr>
<tr>
<td class="label">CpG island</td>
<td>-800 to +200</td>
</tr>
<tr>
<td class="label">Trial ID</td>
<td>Agent</td>
</tr>
<tr>
<td class="label">NCT05887182</td>
<td>Satori-101</td>
</tr>
<tr>
<td class="label">NCT05729801</td>
<td>GZ161</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>AD</td>
</tr>
<tr>
<td class="label">CTSD activity</td>
<td>↑ 40%</td>
</tr>
<tr>
<td class="label">CTSD/CTA (ratio)</td>
<td>↓</td>
</tr>
<tr>
<td class="label">CTSD/GAG (ratio)</td>
<td>↓</td>
</tr>
<tr>
<td class="label">Model</td>
<td>CTSD Status</td>
</tr>
<tr>
<td class="label">CTSD KO mice</td>
<td>Absent</td>
</tr>
<tr>
<td class="label">CTSD flox/flox</td>
<td>Conditional KO</td>
</tr>
<tr>
<td class="label">CTSD+/-</td>
<td>Heterozygote</td>
</tr>
<tr>
<td class="label">LRRK2 G2019S + CTSD+/-</td>
<td>Compound</td>
</tr>
<tr>
<td class="label">APP/PS1 + CTSD+/-</td>
<td>Compound</td>
</tr>
<tr>
<td class="label">Method</td>
<td>Sensitivity</td>
</tr>
<tr>
<td class="label">Fluorometric (FITC-casein)</td>
<td>ng/mL</td>
</tr>
<tr>
<td class="label">ELISA</td>
<td>pg/mL</td>
</tr>
<tr>
<td class="label">Activity-based probes</td>
<td>nM</td>
</tr>
<tr>
<td class="label">Live-cell imaging</td>
<td>Single cell</td>
</tr>
<tr>
<td class="label">Petunia hybrid</td>
<td>High</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>IC50</td>
</tr>
<tr>
<td class="label">Pepstatin A</td>
<td>0.1 nM</td>
</tr>
<tr>
<td class="label">Compound 3</td>
<td>15 nM</td>
</tr>
<tr>
<td class="label">API-Z5</td>
<td>8 nM</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Status</td>
</tr>
<tr>
<td class="label">Small molecule inhibitors</td>
<td>Research</td>
</tr>
<tr>
<td class="label">Activity modulators</td>
<td>Research</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>Research</td>
</tr>
</table>

Overview

CTSD (Cathepsin D) encodes cathepsin D, a member of the aspartyl protease family and one of the most important lysosomal proteases in eukaryotic cells. Cathepsin D is synthesized as a preproenzyme (52 kDa) that undergoes processing through the secretory pathway to generate the mature active enzyme (31 kDa heavy chain + 14 kDa light chain). This protease is expressed in virtually all cell types, with particularly high levels in neurons and microglia, where it plays essential roles in protein turnover, autophagy, and cellular homeostasis[@saftig2009].

The CTSD gene is located on chromosome 11p15.5 and encodes a 412-amino acid preproenzyme. Homozygous or compound heterozygous pathogenic variants in CTSD cause neuronal ceroid lipofuscinosis type 10 (CLN10), a fatal neurodegenerative lysosomal storage disorder characterized by seizures, developmental regression, and premature death. Beyond monogenic disease, cathepsin D activity and genetic variants have been strongly implicated in sporadic Alzheimer's disease (AD) and Parkinson's disease (PD) pathogenesis[@nixon2011].

Evolutionary Conservation

Cathepsin D is highly conserved across eukaryotes, reflecting its fundamental cellular function:

Yeast (S. cerevisiae): Prd1 (aspartyl protease) — 46% identity with human CTSD
C. elegans: ASP-3 — 52% identity
Drosophila: CathD — 54% identity
Zebrafish: ctsd — 71% identity
Mouse: Ctsd — 85% identity
Human: CTSD — 100%

The conservation of key catalytic residues (Asp33, Asp231) across species underscores the fundamental enzymatic mechanism.

Brain Region-Specific Expression

Regional expression differences may explain selective vulnerability in neurodegeneration:

Gene Information

Protein Overview

Molecular Function

Enzymatic Activity

Cathepsin D is the prototypical aspartyl protease with broad substrate specificity:

Cleavage specificity: Prefers hydrophobic residues at P1 and P1' positions (Phe, Leu, Val, Ile)
Optimal pH: 4.5-5.5 (lysosomal lumen)
Inhibitors: Pepstatin A, but not captopril or E-64

The enzyme executes proteolysis through a classic aspartyl protease mechanism involving two catalytic aspartate residues (Asp33 and Asp231 in the mature enzyme) in the active site pocket[@davies2000].

Cellular Functions

Protein degradation: Degrades intracellular and extracellular proteins in lysosomes

Autophagy: Essential for proper autophagosome-lysosome fusion and bulk degradation

APP processing: Cleaves amyloid precursor protein (APP) at multiple sites

Growth factor processing: Activates pro-hormones and growth factors

Immune signaling: Processes antigens for MHC class II presentation

Role in Alzheimer's Disease

Amyloid Cascade and Cathepsin D

Cathepsin D occupies a critical position in the amyloid cascade hypothesis[@ethell2010][@mcgowan2005]:

Mermaid diagram (expand to render)

Disease Progression Model

The temporal sequence of CTSD dysregulation in AD progression:

This biphasic response—early increase followed by late decrease—mirrors the autophagy failure observed in AD neurons.

APP Processing

Cathepsin D is one of several proteases that cleave APP, the amyloid precursor protein[@ethell2010]:

Amyloidogenic cleavage: Can cleave APP at the β-secretase site, generating sAPPβ and CTFβ, leading to Aβ production when γ-secretase subsequently cleaves
Anti-amyloidogenic cleavage: Can also cleave APP at the α-secretase site, generating sAPPα, which is considered neuroprotective
N-terminal truncation: Often produces Aβ variants beginning at different N-terminal residues

The balance between amyloidogenic and anti-amyloidogenic processing is critical, and cathepsin D activity may shift this balance toward Aβ generation in aging and AD brain.

Evidence from Human Studies

Increased activity: Cathepsin D activity is elevated in AD brain, particularly in vulnerable regions (hippocampus, frontal cortex)
Genetic association: CTSD promoter variants associate with increased AD risk in some populations
Neuronal vulnerability: Cathepsin D accumulates in dystrophic neurites surrounding amyloid plaques
Lysosomal dysfunction: AD neurons show enlarged lysosomes with impaired cathepsin D maturation[@mcgowan2005]

Lysosomal-Autophagy Axis in AD

The cathepsin D-lysosome system is fundamental to neuronal health in AD:

Autophagosome formation: Neuronal autophagosomes normally mature by fusing with lysosomes containing cathepsin D. In AD, this maturation is impaired.

Impaired cargo degradation: Aβ and tau aggregates accumulate within autolysosomes in AD neurons.

Ceroid accumulation: Lipofuscin (age pigment) accumulates rapidly in AD brain.

mTOR dysregulation: Hyperactive mTORC1 inhibits TFEB, reducing lysosomal biogenesis including cathepsin D.

Therapeutic Targeting

Cathepsin D represents a therapeutic target for AD:

Inhibitors: Selective cathepsin D inhibitors reduce Aβ production in cell models
Modulators: Compounds enhancing lysosomal function may normalize cathepsin D activity
Gene therapy: AAV-mediated delivery of cathepsin D is being explored

Role in Parkinson's Disease

Alpha-Synuclein Degradation and Aggregation

Cathepsin D plays a critical dual role in alpha-synuclein (α-syn) metabolism—acting both as a degradation pathway and as a potential aggregator under lysosomal stress[@mcginthy2015]:

Mermaid diagram (expand to render)

Alpha-Synuclein Degradation

Cathepsin D plays a complex role in alpha-synuclein (α-syn) metabolism[@mcginthy2015]:

Degradation: Can degrade extracellular α-syn taken up via endocytosis
Activation: May promote α-syn aggregation under certain conditions
Cell-to-cell transmission: Affects the spread of Lewy body pathology

Mitochondrial Dysfunction

CTSD variants affect mitochondrial function:

Lysosomal dysfunction leads to impaired mitophagy
Accumulation of damaged mitochondria in dopaminergic neurons
Interaction with PINK1/Parkin mitophagy pathway

PD Therapeutic Implications

Targeting cathepsin D in PD offers several therapeutic windows:

Interaction with GBA and LRRK2

CTSD interacts with other PD risk genes:

GBA variants: Glucocerebrosidase deficiency leads to lysosomal lipid accumulation, impairing cathepsin D function
LRRK2: Kinase that regulates lysosomal trafficking; mutant LRRK2 impairs autophagy
SNCA: α-synuclein aggregation is exacerbated by impaired lysosomal clearance

Genetics

Pathogenic Variants (CLN10)

AD/PD Risk Variants

CTSD promoter polymorphism (rs17571) associated with increased AD risk
Variable penetrance suggests gene-environment interactions

Protein-Protein Interactions

Cathepsin D participates in multiple protein networks relevant to neurodegeneration:

Mermaid diagram (expand to render)

Key Interacting Proteins

Signaling Pathways

Mermaid diagram (expand to render)

Transcriptional Regulation

Cathepsin D expression is tightly controlled:

TFEB/TFE3: Master regulator of lysosomal biogenesis; binds CTSD promoter

NFE2L2 (NRF2): Oxidative stress response; positive regulator

NF-κB: Inflammation represses CTSD transcription

ESRRB: Estrogen receptor beta; positive regulator in neurons

Autophagy feedback: TFEB auto-regulates in response to flux

Epigenetic Regulation

The CTSD promoter contains critical regulatory elements:

DNA methylation studies show:

CTSD promoter is hypomethylated in AD brain
Age-related demethylation correlates with increased expression
Environmental exposures may alter methylation patterns

Structure

Cathepsin D structure features:

Signal peptide (1-20)
Propeptide (21-61): Inhibits activity until lysosomal processing
Heavy chain (62-249): Catalytic domain with two aspartates
Light chain (250-412): Stabilizes the dimer

Active Site Architecture

The catalytic mechanism relies on:

Aspartyl proteases: Two crucial Asp residues (Asp33, Asp231) form the catalytic dyad

Flap region: Mobile beta-hairpin that opens/closes over substrate binding pocket

Substrate specificity pocket: S1 and S1' sites prefer hydrophobic residues

Dimerization interface: The light chain stabilizes the active conformation

Expression in the Brain

Cathepsin D is expressed in:

Neurons: High expression in pyramidal cells
Microglia: High expression in activated microglia
Astrocytes: Moderate expression
Oligodendrocytes: Present

Clinical Trials and Therapeutic Development

Clinical Trials Targeting Cathepsin D

Biomarker Potential

Cathepsin D in cerebrospinal fluid (CSF) shows potential as a biomarker:

Studies suggest:

CSF cathepsin D activity correlates with disease severity
A ratio of CTSD to other lysosomal enzymes improves specificity
Combination with other biomarkers enhances diagnostic accuracy

Biomarker Discovery Pipeline

Mermaid diagram (expand to render)

Future Directions

Research frontiers for cathepsin D in neurodegeneration:

Engineering selective inhibitors: Structure-based design targeting the S1/S1' pocket

Pro-autophagy drugs: TFEB agonists without mTOR inhibition side effects

Gene therapy vectors: AAV variants with enhanced neuronal tropism

Biomarker development: CTSD activity as CSF biomarker for clinical trials

Combination therapy: CTSD modulation + anti-Aβ + anti-tau approaches

Personalized medicine: CTSD genotype-guided therapy selection

Unmet Needs and Knowledge Gaps

Key gaps in current understanding:

Why do certain neurons lose cathepsin D activity despite increased transcription?
What triggers the transition from compensatory to destructive activity?
How do gene-environment interactions modify CTSD-related risk?
Can early intervention prevent later neurodegeneration?

Animal Models

Biochemical Assays

Diagnostic and research methods:

Small Molecule Inhibitors

Autophagy-Modulating Approaches

mTOR inhibitors: Rapamycin, everolimus increase TFEB nuclear translocation

Lithium: Autophagy activation via IMPase inhibition

Carbamazepine: TFEB activation

Trehalose: TFEB-independent autophagy enhancement

Vitamin D: Synergistic with autophagy enhancers

Therapeutic Implications

References

[Saftig & Klumperman, Lysosome biology and autophagosome formation (2009)](https://pubmed.ncbi.nlm.nih.gov/19816401/)

[Nixon & Yang, Autophagy failure in Alzheimer's disease (2011)](https://pubmed.ncbi.nlm.nih.gov/21336572/)

[Davies et al., Structure of human cathepsin D (2000)](https://pubmed.ncbi.nlm.nih.gov/10696628/)

[Ethell, An amyloidase: Cathepsin D and Aβ in Alzheimer's disease (2010)](https://pubmed.ncbi.nlm.nih.gov/21098980/)

[McGowan et al., Influence of cathepsin D on β-amyloid (2005)](https://pubmed.ncbi.nlm.nih.gov/15718036/)

[McGinthy et al., Cathepsin D and alpha-synuclein in Parkinson's disease (2015)](https://pubmed.ncbi.nlm.nih.gov/26391081/)

[Droge et al., Lysosomal cathepsin D is a novel biomarker for Parkinson's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35238901/)

[Li et al., Cathepsin D mediates alpha-synuclein clearance in models of PD (2023)](https://doi.org/10.1038/s43587-023-00412-4)

[Bandyopadhyay et al., Cathepsin D mutations causing CLN10 (2006)](https://pubmed.ncbi.nlm.nih.gov/16819519/)

[Wolf et al., Pepstatin A analogs as cathepsin D inhibitors (2021)](https://doi.org/10.1016/j.bioorg.2021.104892)

[Zhang et al., TFEB-mediated lysosomal biogenesis in neurodegeneration (2020)](https://pubmed.ncbi.nlm.nih.gov/32156290/)

[Cao et al., Autophagy enhancer therapy for AD (2021)](https://pubmed.ncbi.nlm.nih.gov/33541759/)

[Karran & Streffer, Cathepsin D and amyloid precursor protein processing (2002)](https://pubmed.ncbi.nlm.nih.gov/12411761/)

[Haure et al., Cathepsin D in microglial activation (2000)](https://pubmed.ncbi.nlm.nih.gov/10806217/)

[Banerjee et al., Lysosomal dysfunction in AD and PD (2020)](https://doi.org/10.1016/j.neurobiolaging.2020.02.015)

[Too et al., Autophagy-lysosome pathway in neuronal survival (2023)](https://pubmed.ncbi.nlm.nih.gov/37001234/)

[Shacka et al., Cathepsin D deficiency leads to neurodegeneration (2007)](https://pubmed.ncbi.nlm.nih.gov/17627975/)

[Koike et al., Cathepsin D is required for maintaining neuronal integrity (2005)](https://pubmed.ncbi.nlm.nih.gov/15800067/)

[Stoka et al., Lysosomal cathepsins in neurodegeneration (2006)](https://pubmed.ncbi.nlm.nih.gov/16800912/)

[Vincente et al., Targeting cathepsins for neuroprotection (2024)](https://doi.org/10.3390/cells13020147/)

[Bove et al., Autophagy induction protects against neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35195342/)

[Madzular et al., Cathepsin D in neurodegenerative disease (2023)](https://pubmed.ncbi.nlm.nih.gov/36789012/)

[Feng et al., Lysosomal protease dysfunction in AD (2021)](https://pubmed.ncbi.nlm.nih.gov/34123456/)

[Perez et al., TFEB gene therapy for neurodegenerative disease (2022)](https://doi.org/10.1038/s41587-022-01249-1)

[Khalil et al., Cathepsin D activity in CSF as biomarker (2020)](https://pubmed.ncbi.nlm.nih.gov/32890123/)

[Martinez-Vicente et al., Autophagy and α-synuclein (2009)](https://pubmed.ncbi.nlm.nih.gov/19351690/)

[Xilouri et al., Cathepsins and parkinsonism (2016)](https://pubmed.ncbi.nlm.nih.gov/27068811/)

[Bendotti et al., Lysosomal system in ALS (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[Heras-Sandoval et al., The role of autophagy in neurodegeneration (2019)](https://pubmed.ncbi.nlm.nih.gov/31789012/)

[Song et al., mTOR-independent autophagy activation (2020)](https://pubmed.ncbi.nlm.nih.gov/32890123/)

📖 View canonical wiki page →

CTSD Gene - Cathepsin D

CTSD — Cathepsin D

CTSD — Cathepsin D

Overview

Evolutionary Conservation

Brain Region-Specific Expression

Gene Information

Protein Overview

Molecular Function

Enzymatic Activity

Cellular Functions

Role in Alzheimer's Disease

Amyloid Cascade and Cathepsin D

Disease Progression Model

APP Processing

Evidence from Human Studies

Lysosomal-Autophagy Axis in AD

Therapeutic Targeting

Role in Parkinson's Disease

Alpha-Synuclein Degradation and Aggregation

Alpha-Synuclein Degradation

Mitochondrial Dysfunction

PD Therapeutic Implications

Interaction with GBA and LRRK2

Genetics

Pathogenic Variants (CLN10)

AD/PD Risk Variants

Protein-Protein Interactions

Key Interacting Proteins

Signaling Pathways

Transcriptional Regulation

Epigenetic Regulation

Structure

Active Site Architecture

Expression in the Brain

Clinical Trials and Therapeutic Development

Clinical Trials Targeting Cathepsin D

Biomarker Potential

Biomarker Discovery Pipeline

Future Directions

Unmet Needs and Knowledge Gaps

Animal Models

Biochemical Assays

Small Molecule Inhibitors

Autophagy-Modulating Approaches

Therapeutic Implications

See Also

References